Praxis Precision Medicines (PRAX)

• Market cap: $4.45B
• 1 day: -3.01%
• 5 days: 4.65%
• 1 month: 240.24%
• 3 months: 263.06%
• 6 months: 377.17%
• Year to date: 123.94%
• 1 year: 117.91%
• 5 years: -64.87%
• 10 years: -57.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Employees: 82